Momelotinib for myelofibrosis with enlarged spleen
Part of Blood & lymphatic clinical trials.
This trial is studying the effectiveness of momelotinib, a JAK inhibitor, for people with myelofibrosis who have an enlarged spleen. It aims to see how well the drug works in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have primary myelofibrosis, or myelofibrosis that started after polycythemia vera or essential thrombocythemia.
- Your doctor has confirmed your spleen is enlarged (palpable splenomegaly) before starting momelotinib.
- You are not in an advanced (accelerated or blast) phase of myelofibrosis.
- Your platelet count is 20 or higher (×10^9/L) before starting momelotinib.
- You have not used JAK inhibitors for other conditions besides myelofibrosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This trial tests a new oral medicine, flonoltinib maleate, to see if it can help reduce spleen size and improve symptoms in people with myelofibrosis, a type of blood disorder. The study enrolls patients who have not responded to other treatments or have not had JAK inhibitor therapy (or only briefly).
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
This trial tests a new combination of two drugs, bomedemstat and momelotinib, for people with myelofibrosis. It aims to see if adding bomedemstat can help when momelotinib alone isn't working well enough, or for those with low blood counts.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.